NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

AgomAb Therapeutics NV (AGMB) Stock Analysis

AgomAb Therapeutics NV (AGMB) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

AGMB

$9.11

+$0.38 (+4.35%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare AGMB with… →

AGMB Key Statistics

As of Oct 21, 2026
Trading
Open
$8.74
Previous Close
$8.73
Day's Range
8.74–9.22
52-Week Range
7.92–17.82
Volume
42.42K
Valuation
Market Cap
$448.65M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−2.08
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$62.55M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
49.25M
Dividend and dates
Avg Volume
137.55K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

AgomAb Therapeutics NV (AGMB) has a market capitalization of $448.65M.

In fiscal 2025, AGMB reported revenue of $0.00.

AGMB Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$62.55M—
2024$0.00−$46.27M—
2023$0.00−$11.39M—
2022$0.00−$8.14M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$59.28M−$62.55M—
2024$0.00—−$48.02M−$46.27M—
2023$0.00—−$31.19M−$11.39M—
2022$0.00—−$22.63M−$8.14M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 17 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values AgomAb Therapeutics NV (AGMB) at $448.65M. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 62 employees.

AGMB last closed at $9.11 on October 21, 2026. That is +$0.38 (+4.35%) against the previous close. Over the past 52 weeks the price has ranged from $7.92 to $17.82. The latest close sits 15.03% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $62.55M. Trailing earnings per share are −2.08.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

The stored price history starts on February 6, 2026, and the total return since then is −37.82%.

Growth & Income

No dividend is on file for AGMB.

2026 is still running; the total return is −37.82% year to date.

Peer Comparison

AgomAb Therapeutics NV (AGMB) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
AgomAb Therapeutics NV AGMB $448.65M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. AgomAb Therapeutics NV has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About AgomAb Therapeutics NV

AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States. The company's product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenosing Crohn's disease, which is in Phase 2a clinical trials; and AGMB-447, an inhaled small molecule inhibitor of ALK5 or TGFßR1 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1 clinical trials. It also develops AGMB-101, a HGF-mimetic monoclonal antibody that acts through agonism or stimulation of the MET receptor and has demonstrated antifibrotic and regenerative activity in preclinical models. The company was incorporated in 2017 and is headquartered in Antwerp, Belgium.

Visit website →